ATAGI (Australian Technical Advisory Group on Immunisation) has published a statement on the clinical use of Arexvy, a respiratory syncytial virus (RSV) vaccine, for the prevention of RSV in older adults in Australia. 

Respiratory syncytial virus (RSV) is one of the leading causes of respiratory tract infections in young children and is associated with severe respiratory disease in people aged over 60 years.   

Arexvy is available on the private market, and is recommended for: 

  • all adults aged over 75 years 
  • First Nations Australians aged 60 to 74 years 
  • Non-Indigenous Australians with medical conditions that increase their risk of severe disease due to RSV. 

ATAGI’s full statement includes further details on recommendations, contraindications, coadministration, RSV and Arexvy.

A new chapter on RSV will be available in the Australian Immunisation Handbook by mid-2024. Until then, use the ATAGI statement for clinical guidance. 

ATAGI: Statement on the clinical use of Arexvy